Understanding the anti-cancer effects of new YAP/TAZ inhibitors to treat malignant mesothelioma KU Leuven
Asbestos exposure causes malignant mesothelioma, for which there are no effective therapies available. The most frequent driver mutations of
mesothelioma are mutations in the Hippo pathway that cause the hyperactivation of its downstream effectors, the transcriptional co-activators
YAP and TAZ. Therefore, the Hippo pathway, and in particular the activity of YAP/TAZ, is one of the most promising targets to develop novel targeted ...